It is reported that recently, the Department of Surgical Oncology of our hospital introduced a thermal perfusion therapy instrument and successfully carried out the new technology of malignant tumor abdominal thermal perfusion chemotherapy. The first patient who received the treatment had a satisfactory initial effect and is currently undergoing follow-up treatment and follow-up as planned. Patient Liang XX, female, 43 years old, resident of Qishi Town, Dongguan, China, hospitalization number: 624208, was hospitalized in our hospital in April 2013 and diagnosed as gastric body cancer. The patient recovered well after surgery and started 6 courses of systemic adjuvant chemotherapy two weeks after surgery, followed up by regular outpatient visits. In April of this year, the patient was found to have a new pelvic mass on repeat ultrasound, and after further examination in hospital, tumor marker CA199: 1231.9 U/ml, MRI showed two masses in the posterior pelvic uterus, the larger one 41mmX33mm, and pelvic metastatic cancer was considered. A hard, grayish-white mass measuring about 100pxX75px was detected intraoperatively, which was clearly a metastatic gastric cancer implant (Krukenberg’s tumor). The tumor marker CA199 decreased to 80.81 U/ml on the 25th postoperative day, and the tumor marker CA199 decreased to normal level (30.72 U/ml) on the latest hospitalization (June 8). The patient is currently under follow-up treatment as planned, generally doing well and living a normal life. Studies have shown that the temperature tolerated by tumor cells is only 43℃, while normal tissues can tolerate more than 1 hour at 47℃ without damage. Intraperitoneal thermal perfusion chemotherapy precisely takes advantage of the difference in temperature tolerance ability between normal tissue cells and tumor cells, and instills the liquid containing chemotherapeutic drugs into the abdominal cavity after heating by physical methods, so that the local temperature of the abdominal cavity rises to 43℃ and is maintained for a certain period of time to achieve the therapeutic purpose of not only causing apoptosis of tumor cells, but also not damaging normal tissues. Tumor thermal perfusion therapy can also increase the sensitivity of chemotherapeutic drugs, increase cell membrane permeability and aggravate DNA damage of tumor cells; increase anaerobic filialysis of tumor cells, decrease pH value and increase killing power; reduce or prevent cancer cells from producing drug resistance; heat therapy makes the blood supply around the tumor rich, so as to achieve higher drug concentration and efficacy, because peritoneal thermal perfusion therapy is local treatment, compared with traditional intravenous chemotherapy In contrast to traditional intravenous chemotherapy, the administration of intraperitoneal chemotherapy increases the concentration of anticancer drugs in the peritoneal cavity and prolongs the contact time between drugs and cancer cells. As a method of treating thoracic malignant tumor, continuous circulating peritoneal thermal perfusion chemotherapy is less invasive, safe and painless, with fast recovery and good control of ascites, and has good application prospects. The successful development of abdominal thermal perfusion chemotherapy in our oncology surgery department has provided a new means and brought new hope for the treatment of tumor patients in our city, especially those with thoracic and abdominal cavity tumors!